Abstracts Archive - Page 693 of 2425 - ACR Meeting Abstracts

Abstract Number: 0981 • ACR Convergence 2020
Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic Status: The California Lupus Surveillance Project, 2007-2017
Milena Gianfrancesco¹, Maria Dall'Era², Louise Murphy³, Charles Helmick³, Jing Li¹, Stephanie Rush¹, Laura Trupin¹ and Jinoos Yazdany⁴, ¹University of California, San Francisco, San Francisco, CA, ²Division of Rheumatology, University of California, San Francisco, CA, ³Centers for Disease Control and Prevention, Atlanta, GA, ⁴UCSF, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease with manifestations that vary widely in severity. Contemporary data indicate that minority populations are at…
Abstract Number: 0987 • ACR Convergence 2020
Efficacy and Safety of Iberdomide in Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Randomized, Placebo-Controlled Study
Joan Merrill¹, Victoria Werth², Richard Furie³, Ronald van Vollenhoven⁴, Milan Petronijevic⁵, Benito Velasco Zamora⁶, Maria Majdan⁷, Fedra Irazoque-Palazuelos⁸, Michael Weiswasser⁹, Shimon Korish⁹, Peter Schafer⁹, Zhaohui Liu⁹, Allison Gaudy⁹, Nataliya Agafonova⁹ and Nikolay Delev⁹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Military Medical Academy, Belgrade, Serbia, ⁶Instituto CER S.A., Buenos Aires, Argentina, ⁷Medical University of Lublin and Samodzielny Publicnzy Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland, ⁸Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, ⁹Bristol Myers Squibb, Princeton
Background/Purpose: Iberdomide is a high-affinity cereblon ligand that promotes ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors linked to the genetic…
Abstract Number: 0986 • ACR Convergence 2020
BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus
Victoria Werth¹, Richard Furie², Juanita Romero-Díaz³, Sandra Navarra⁴, Kenneth Kalunian⁵, Ronald van Vollenhoven⁶, Filippa Nyberg⁷, Benjamin Kaffenberger⁸, Saira Sheikh⁹, Goran Radunovic¹⁰, Xiaobi Huang¹¹, Hua Carroll¹², Francois Gaudreault¹², Adam Meyers¹¹, Catherine Barbey¹³, Cristina Musselli¹¹ and Nathalie Franchimont¹¹, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁴University of Santo Tomas, Manila, Philippines, ⁵University of California San Diego, La Jolla, CA, ⁶Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁷Karolinska University Hospital, Stockholm, Sweden, ⁸Ohio State University, Columbus, OH, ⁹Division of Rheumatology, Allergy and Immunology, University of North Carolina, Chapel Hill, NC, ¹⁰Institute of Rheumatology, University of Belgrade, Belgrade, Serbia, ¹¹Biogen, Cambridge, MA, ¹²Biogen, Cambridge, ¹³Biogen, Baar, Switzerland
Background/Purpose: No approved targeted therapies have been developed for cutaneous lupus erythematosus (CLE), a disfiguring autoimmune disease that severely impairs quality of life.1 BIIB059 is…
Abstract Number: 0992 • ACR Convergence 2020
Impact of Selective Inhibitors of Nuclear Export on SLE Plasma Cells Is Modulated by the BM Microenvironment
Neha Nandedkar-Kulkarni¹, Nida Meednu², Jennifer Albrecht², Jennifer Barnas², Douglas Widman³ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical center, Rochester, NY, ³Karyopharm Therapeutics, Newton, MA
Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disorder with heterogeneous disease presentation and a multi-pronged pathogenesis. Although autoreactive plasma cells play a key…
Abstract Number: 0994 • ACR Convergence 2020
Does Tofacitinib Impact B Cell Functions?
Guillaume Decarriere¹, Julie Mielle², Bernard Combe³, Jacques Morel¹, Rachel Audo² and Claire Daien¹, ¹Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, ²Institut de génétique moléculaire de Montpellier (IGMM), Montpellier, France, ³University of Montpellier, Montpellier, France
Background/Purpose: Tofacitinib (tofa) inhibits cytokine signaling mediated by JAK1 JAK3 pathways leading therefore to a decrease in Th17 and an increase of Treg cells. The…
Abstract Number: 0989 • ACR Convergence 2020
Withdrawal of MMF Is Safe in Quiescent Renal and Non-Renal SLE: Results from a Multi-Center Randomized Trial
Eliza Chakravarty¹, Tammy Utset², Diane Kamen³, Gabriel Contreras⁴, W. Joseph McCune⁵, Kenneth Kalunian⁶, Cynthia Aranow⁷, Megan Clowse⁸, Elena Massarotti⁹, Ellen Goldmuntz¹⁰, Jessica Springer¹⁰, Lynette Keyes-Elstein¹¹, Bill Barry¹¹, Ashley Pinckney¹¹ and Judith James¹², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Chicago, Chicago, IN, ³Medical University of South Carolina, Charleston, SC, ⁴University of Miami Miller School of Medicine, Miami, ⁵University of Michigan, Ann Arbor, MI, ⁶University of California San Diego, La Jolla, CA, ⁷Feinstein Institutes for Medical Research, Manhasset, NY, ⁸Duke University, Chapel Hill, NC, ⁹Brigham and Women's hospital, Boston, MA, ¹⁰NIH/NIAID, Rockville, MD, ¹¹Rho, Durham, NC, ¹²Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Mycophenolate Mofetil (MMF) is standard of care therapy for long term treatment of lupus nephritis and other manifestations of SLE. However, it is associated…
Abstract Number: 0984 • ACR Convergence 2020
Neighborhood Deprivation and Race/Ethnicity Affects COVID-19 Risk and Severity in SLE
Ashira Blazer¹, Ruth Fernandez-Ruiz², Mala Masson², Rebecca Haberman³, Rochelle Castillo⁴, Jose Scher⁴, Huda Algasas⁵, Allison Guttmann², Philip Carliucci³, Kristina Deonaraine², Michael Golpanian⁶, Kimberly Robins², Miao Chang², H. Michael Belmont⁶, Jill Buyon⁷, Amit Saxena³ and Peter Izmirly⁶, ¹NYU School of Medicine, New York, NY, ²New York University School of Medicine, New York, ³NEW YORK UNIVERSITY SCHOOL OF MEDICINE, New York, NY, ⁴NYU School of Medicine, New York City, ⁵Columbia University, New York, NY, ⁶New York University, New York, NY, ⁷Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Disparities have been reported during the coronavirus disease (COVID-19) outbreak. Systemic lupus erythematosus (SLE) patients represent a unique group that is affected by clinical,…
Abstract Number: 0997 • ACR Convergence 2020
Novel Shared Antibody Specificities in Ro Antibody Negative Sjögren’s Syndrome
Sherri Longobardi¹, Constantin Georgescu², Christina Lawrence³, Charmaine Moya³, Jonathan Wren⁴, Judith James⁵, Kathy Sivils³ and A. Darise Farris⁶, ¹Graduate Program in Biological Sciences, University of Oklahoma Health Sciences Center; Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Sjögren’s syndrome (SS) is a rheumatic autoimmune disease characterized by focal lymphocytic infiltrates in the lacrimal and salivary glands, severe dry mouth and eyes,…
Abstract Number: 1000 • ACR Convergence 2020
Passive Smoking Throughout the Life Course and the Risk of Incident Rheumatoid Arthritis in Adulthood Among Women
Kazuki Yoshida¹, Jiaqi Wang², Susan Malspeis³, Bing Lu⁴, Lauren C. Prisco³, Lily Martin³, Julia Ford², Karen Costenbader⁵, Elizabeth Karlson² and Jeffrey Sparks⁶, ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Personal cigarette smoking has been strongly associated with the risk for developing seropositive RA. Previous studies concerning passive smoking conflict; some suggested that childhood…
Abstract Number: 1001 • ACR Convergence 2020
Risk of Malignant Melanoma and Nonmelanoma Skin Cancer in Rheumatoid Arthritis Patients Initiating Methotrexate versus Hydroxychloroquine
Hemin Lee¹, Sarah Chen², Nileesa Gautam², Seanna Vine¹, Mengdong He², Rishi Desai², Michael Weinblatt¹, Robert Glynn² and Seoyoung Kim², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston
Background/Purpose: Previous randomized clinical trials and observational studies have signaled an increased risk of skin cancer in rheumatoid arthritis (RA) patients treated with immunosuppressants such…
Abstract Number: 0996 • ACR Convergence 2020
Bacteria-Derived Indole Drives Autoimmune Arthritis by Altering B Cell Glycosylation of Autoantibodies
Brandon Trent¹, Meagan Chriswell², Widian Jubair³ and Kristine Kuhn¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²UC Denver SOM, Denver, CO, ³University of Colorado Denver, Denver, CO
Background/Purpose: Background: Dysbiosis of gut bacterial communities in rheumatoid arthritis (RA) is a noted phenomenon in both murine models and human patients; however, the mechanisms…
Abstract Number: 1007 • ACR Convergence 2020
Atopic Dermatitis and Risk of Incident Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Thanitsara Rittiphairoj¹, Nipith Charoenngam¹, Ben Ponvilawan¹, Surapa Tornsatitkul¹, Phuuwadith Wattanachayakul¹, Pongprueth Rujirachun¹ and Patompong Ungprasert², ¹Mahidol University, Bangkok, Thailand, ²Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH
Background/Purpose: Recent observational studies have suggested that patients with atopic dermatitis (AD) may have a higher risk of several non IgE-mediated inflammatory disorders, such as…
Abstract Number: 1004 • ACR Convergence 2020
The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Rheumatoid Arthritis Patients
Soumyasri Kambhatla¹, Estefania Gauto-Mariotti² and Augustine Manadan³, ¹John H Stroger Hospital of Cook County, Riverside, IL, ²John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Streptococcus pneumoniae, Herpes zoster, and influenza infections are common and potentially preventable causes of morbidity and mortality. Vaccinations have been shown to reduce infection…
Abstract Number: 0999 • ACR Convergence 2020
CXCL13 Is a Key Driver for Migration and Differentiation of Regulatory B Cells
Claire Rempenault¹, Julie Mielle², Kristina Schreiber¹, Pierre Corbeau³, Jacques Morel⁴, Claire Daien⁴ and Rachel Audo², ¹Rheumatology, Montpellier, France, ²Institut de génétique moléculaire de Montpellier (IGMM), Montpellier, France, ³immunology, Nimes, France, ⁴Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France
Background/Purpose: Human regulatory B cells still need to be characterized. Given the absence of phenotypical definition, a functional definition based on their ability to secrete…
Abstract Number: 0891 • ACR Convergence 2020
Four-Year Efficacy and Safety of Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis from VOYAGE 1 and VOYAGE 2
Kristian Reich¹, Jan Dutz², Peter Foley³, Diamant Thaçi⁴, Ron Vender⁵, Michael Song⁶, Megan Miller⁶, Yin Yu⁶, Shu Li⁷, Yaung-Kaung Shen⁶ and April W. Armstrong⁸, ¹Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation®, Hamburg, Germany, ²Vancouver General Hospital, Vancouver, Canada, ³University of Melbourne, St. Vincent’s Hospital, Melbourne and Skin & Cancer Foundation Inc, Carlton, Australia, ⁴Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁵McMaster University, Hamilton, Canada, ⁶Janssen Research & Development, LLC, Spring House, ⁷Janssen Scientific Affairs, LLC, Horsham, ⁸Keck School of Medicine of University of Southern California, Los Angeles, CA
Background/Purpose: Guselkumab (GUS), a fully human monoclonal antibody, selectively binds and blocks IL-23. VOYAGE 1 and VOYAGE 2 are two ongoing Phase 3, randomized, double-blind,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].